Safer Antipsychotic Prescribing in Dementia: Latest Info

This mini conference will provide attendees with up to date information from the latest research on antipsychotic safety in dementia and the tools to incorporate this into clinical decision making. This includes new data from a Brunel University London NIHR-funded project examining the influence of patient cardiovascular disease history on risperidone safety in dementia. Attendees will also have the opportunity to provide feedback on a draft of a new decision aid based on these data.

There will be four talks (~20 mins plus ~10 min Q&A) following by a workshop.

Objectives

• To explore non-pharmacological interventions for managing behavioural and psychological symptoms in dementia
• To understand patient, clinician, and carer perspectives on antipsychotic use and the effective communication of associated side effect risks
• To assess evidence around safer antipsychotic prescribing practices, including the influence of cardiovascular history on stroke risk and appropriate clinical indications

Register to Attend

8:30 AM – 8:55 AM | Registration, Coffee and Pastries

8:55 AM – 9:00 AM | Opening Remarks

Speaker: Dr Byron Creese

9:00 AM – 9:30 AM | Talk 1: Non-Pharmacological Interventions for Behavioural and Psychological Symptoms in Dementia

· Review of evidence-based non-pharmacological strategies

· Discussion on implementation challenges and clinician support needs

Speaker: Dr Zunera Khan, King’s College London

9:30 AM – 10:00 AM | Talk 2: Patient, Clinician, and Carer Views on Antipsychotic Use and Risk Communication

· Insights into communication practices and perceptions of risk

· Strategies to enhance shared decision-making

Speaker: Dr Louis Stokes and Dougy Macfarlane, University of Sheffield and Brunel University London

10:00 AM – 10:30 AM | Break & Refreshments

10:30 AM – 11:00 AM | Talk 3: Cardiovascular Clinical History and Stroke Risk in Antipsychotic Prescribing.

· How cardiovascular history influences risk when prescribing antipsychotics.

· Practical applications for patient risk stratification.

Speaker: Dr Byron Creese, Brunel University London

11:00 AM – 11:30 AM | Talk 4: Appropriate Indications for Antipsychotic Use in Dementia Care

· Overview of evidence supporting specific indications

· Recommendations for safe prescribing practices in complex cases

Speaker: Dr Christoph Mueller, King’s College London and South London and Maudsley NHS Foundation Trust.

11:15 AM – 12:00 PM | Workshop: Clinician Input on a Draft Decision Aid for Risperidone Prescribing in Dementia

· Presentation of the decision aid prototype

· Interactive feedback session on usability, clinician needs, and barriers

Facilitators: Dr Byron Creese, Dr Louis Stokes, Dougy Macfarlane.

12:00 PM – 12:30 PM | Lunch and Networking

Lunch provided; an opportunity for informal discussion and networking

12:30 PM | Conference Close